No Data
VENUS MEDTECH-B announced that it will resume trading at 9:00 AM on March 13.
VENUS MEDTECH-B (02500) announced that its shares will resume trading at 9:00 AM on March 13, 2025.
VENUS MEDTECH-B (02500.HK) has met all resumption guidelines and will resume trading tomorrow.
Gelonghui, March 12 | VENUS MEDTECH-B (02500.HK) announced that the company has met all resumption guidelines. The company has applied to resume trading of its shares on the Stock Exchange from 9:00 AM on March 13, 2025.
The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.
On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China, from drug development and diagnostics to Hospital management, will benefit from the AI revolution.
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
AI hotspots continue to boost! Most Medical stocks in Hong Kong strengthen, with Micro-invasion Siasun Robot&Automation rising over 20%.
How does Sister Wood perceive this hot topic of AI Medical? What positive impacts will the emergence of DeepSeek bring to the medical field?
Qiming Medical -B (02500) plans to appoint Gu Junhua as an independent non-executive director.
Qiming Medical - B (02500) issued an announcement, the board of directors decided to convene the company's second extraordinary shareholder meeting in 2024...
